Lonsurf (trifluridine/tipiracil)

Numéro de dossier de l’AMC: 22614
État des négociations:
En négociation
Indication(s):
LONSURF, in combination with bevacizumab, for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents.
Promoteur/fabricant:
Taiho Pharma Canada Inc.
Numéro de projet de l’AMC:
PC0330-000
Lettre-contrat de l’APP:
Conclusion du processus de négociation:
Sans objet